Hong Kong Stock Movement
CLOUDBREAK-B fell 15.30%. Based on recent key news:
<ol>
<li>
On December 8, CLOUDBREAK-B announced that its subsidiary Cloudbreak USA will hold a post-phase 2 clinical trial meeting with the U.S. Food and Drug Administration on December 10 to discuss the development progress of the candidate drug CBT-004 and potential phase 3 clinical trial development. This news attracted market attention, leading to stock price fluctuations. Source: Zhitong Finance
</li>
<li>
On December 8, CLOUDBREAK-B's stock price rose 9.75% after the news was announced at noon, but then experienced a significant decline, indicating market uncertainty regarding expectations for the post-clinical trial meeting. Source: Caihua News
</li>
<li>
On December 8, Economic Information Daily reported on CLOUDBREAK-B's post-clinical trial meeting arrangements, emphasizing its importance in the development process. The market reacted variably to this news, resulting in stock price fluctuations. Source: Economic Information Daily. The industry faces risks of uncertainty in the development process.
</li>
</ol>
Stocks with High Trading Volume in the Industry
Innovent Biologics fell 0.06%. Based on recent key news:
<ol>
<li>
On December 8, Innovent Biologics announced that its 7 innovative products were successfully included in the new version of the medical insurance catalog. After the announcement, the stock price fell by about 7%. Investors are concerned that the inclusion of Eli Lilly's tirzepatide in the medical insurance catalog may pressure Innovent Biologics' sales of sintilimab. Source: Zhitong Finance
</li>
<li>
On December 9, JP Morgan reported that the decline in Innovent Biologics' stock price was related to the results of the national medical insurance drug catalog negotiations, with investors worried that Innovent Biologics might significantly reduce the prices of small molecule inhibitor drugs to gain insurance coverage. Source: JP Morgan
</li>
<li>
On December 10, UBS released a research report stating that six new products from Innovent Biologics and new indications for sintilimab have been included in the medical insurance catalog, and it is expected that sales of new products will achieve rapid growth by 2026. Source: UBS. Pharmaceutical industry innovation drug catalog update.
</li>
</ol>
Rongchang Biologics rose 1.30%. Based on recent news:
<ol>
<li>
On December 7, the National Healthcare Security Administration released the new version of the medical insurance catalog for 2025, adding 114 new drugs, of which 50 are category 1 innovative drugs. This policy encourages the development of innovative drugs, significantly benefiting Rongchang Biologics as an innovative drug company, leading to a rise in stock price.
</li>
<li>
On December 7, the success rate of national medical insurance negotiations reached a record high of 88%. This high success rate demonstrates the policy's support for innovative drugs, further boosting market confidence in Rongchang Biologics and driving up stock prices.
</li>
<li>
On December 7, the first commercial health insurance innovative drug catalog was released, including 19 drugs. As an innovative drug company, Rongchang Biologics benefits from policy dividends, and the market expects its future performance to improve, resulting in a rise in stock price. The innovative drug industry is favored by policy, and market expectations are positive.
</li>
</ol>
Kangfang Biologics rose 0.68%. Based on recent key news:
<ol>
<li>
On December 10, the National Healthcare Security Administration announced the results of the negotiation for the innovative drug catalog, with multiple products from CanSino Biologics gaining new coverage, boosting market confidence. According to Zhitong Finance, the introduction of commercial insurance funds will bring incremental capital for innovative drug payments, driving stock prices up.
</li>
<li>
On December 8, CanSino Biologics announced that five of its new drugs were included in the National Healthcare Catalog for 2025, expected to be implemented on January 1 next year. Economic Information Daily pointed out that this will improve the level of clinical medication and enhance market expectations for the company's future growth.
</li>
<li>
On December 9, CanSino Biologics showcased its key clinical trial results at the ESMO Asia Congress, further consolidating its leading position in the innovative drug field. The latest research data released by the company has strengthened investors' confidence in its R&amp;D capabilities. The pharmaceutical industry's innovative drug development potential is significant.
</li>
</ol>
Stocks ranked among the top in industry market capitalization
BeiGene has a market capitalization of HKD 292.3 billion. Based on recent key news:
<ol>
<li>
On December 8, the National Healthcare Security Administration released a new version of the drug catalog, with two of BeiGene's drugs included in the commercial insurance innovative drug catalog, driving stock price fluctuations. The new catalog will be implemented on January 1, 2026, with a success rate reaching a historical high. Source: Zhitong Finance
</li>
<li>
On December 10, BeiGene signed a strategic cooperation agreement with Shengxiang Biotechnology to promote an integrated diagnosis and treatment strategy, further enhancing market confidence. Source: Zhitong Finance
</li>
<li>
On December 9, analysts expect BeiGene to achieve positive profits and positive free cash flow, driving stock prices up. Source: Daiwa Capital Markets, with increased policy support for the innovative drug industry
</li>
</ol>

02592

CLOUDBREAK-B fell 15.30%; Innovent Biologics fell 0.06%, with a transaction volume of HKD 527 million; Rongchang Biologics rose 1.30%, with a transaction volume of HKD 471 million; CanSino Biologics rose 0.68%, with a transaction volume of HKD 460 million; BeiGene's market value reached HKD 292.3 billion

Hong Kong Stock Movement: CLOUDBREAK-B fell 15.3%, clinical trial meeting triggers market uncertainty